Savara Inc (NASDAQ:SVRA) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP grew its holdings in Savara Inc (NASDAQ:SVRA) by 22.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,624,012 shares of the company’s stock after purchasing an additional 1,608,522 shares during the quarter. Wellington Management Group LLP owned about 0.05% of Savara worth $36,566,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Frazier Life Sciences Management L.P. grew its position in shares of Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Vestal Point Capital LP grew its holdings in Savara by 24.7% in the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after buying an additional 1,600,000 shares in the last quarter. Jennison Associates LLC grew its holdings in Savara by 17.5% in the 3rd quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after buying an additional 1,001,296 shares in the last quarter. Nantahala Capital Management LLC increased its stake in shares of Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. Finally, Farallon Capital Management LLC boosted its position in shares of Savara by 90.5% during the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock valued at $18,377,000 after acquiring an additional 2,165,701 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SVRA has been the topic of a number of analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, HC Wainwright reduced their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Insider Buying and Selling

In other news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the purchase, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.13% of the company’s stock.

Savara Price Performance

Savara stock opened at $3.35 on Friday. The company’s 50 day moving average is $3.54 and its two-hundred day moving average is $4.03. The firm has a market cap of $574.92 million, a PE ratio of -7.72 and a beta of 0.92. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 52-week low of $2.82 and a 52-week high of $5.70.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, research analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.